NEW YORK, NY / ACCESSWIRE / April 1, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
fuboTV Inc. (NYSE:FUBO)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/fubotv-inc-loss-submission-form?prid=14284&wire=1
Lead Plaintiff Deadline: April 19, 2021
Class Period: March 23, 2020 - January 4, 2021
Allegations against FUBO include that: (ii) Fubo offering of products was subject to undisclosed cost escalations; (iii) Fubo could not successfully compete and perform as sports book operator and could not capitalize on its only sports wagering opportunity; (iv) Fubo's data and inventory was not differentiated to allow Fubo to achieve long-term advertising growth goals and forecasts; (v) Fubo's valuation was overstated in light of its total revenue and subscription levels; (vi) the acquisition of Balto Sport did not provide the stated synergies, internal expertise, and did not expand the Company's addressable market into online sports wagering; and as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (NASDAQ:HSACW)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-loss-submission-form?prid=14284&wire=1
Lead Plaintiff Deadline: April 20, 2021
Class Period: October 2, 2019 - February 1, 2021
Allegations against HSACW include that: (i) HSAC had performed inadequate due diligence into Legacy Immunovant prior to the Merger, and/or ignored or failed to disclose safety issues associated with IMVT-1401; (ii) IMVT-1401 was less safe than the Company had led investors to believe, particularly with respect to treating TED and WAIHA; (iii) the foregoing foreseeably diminished IMVT-1401's prospects for regulatory approval, commercial viability, and profitability; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Neptune Wellness Solutions Inc. (NASDAQ:NEPT)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/neptune-wellness-solutions-inc-loss-submission-form?prid=14284&wire=1
Lead Plaintiff Deadline: May 17, 2021
Class Period: July 24, 2019 - February 16, 2021
Allegations against NEPT include that: (i) the cost of Neptune's integration of the assets and operations acquired in the SugarLeaf Acquisition would be larger than the Company had acknowledged, placing significant strain on the Company's capital reserves; (ii) accordingly, it was reasonably foreseeable that the company would need to conduct additional stock offerings to raise more capital; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong